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Abstract
Acute leukemia is the most common childhood malignancy, accounting for almost 
35% of all childhood cancers. Acute myeloid leukemia (AML) represents 15–20% of 
pediatric acute leukemia. Majority of AML cases appear de novo, however a minority 
of cases can present as a secondary malignancy. AML is a highly heterogeneous dis-
ease and its diagnosis involves a combination of diagnostic analyses including mor-
phology, immunophenotyping, cytochemistry, and leukemic blasts derived from 
peripheral blood or bone marrow demonstrating cytogenic and molecular charac-
teristics. Through the identification of recurrent genetic mutations, it has been made 
possible to refine individual prognosis and guide therapeutic management. The cur-
rent survival rate of children with AML is approximately 70%. The standard thera-
peutic regimen is a combination of cytarabine- and anthracycline-based regimens 
with allogenic stem cell transplantation in appropriate patients. Relapse in pediatric 
patients suffering from AML occurs in approximately 30% of cases, whereas death 
occurs in 5–10% of patients as a result of disease complications or chemotherapeutic 
side effects. In understanding the genetic basis of AML, targeted therapies will have 
the ability to reduce treatment-related morbidity and mortality. Here, we provide a 
comprehensive review of AML, its biology, diagnosis and therapeutic management 
in pediatric patients.
Keywords: acute myeloid leukemia, pediatrics, diagnosis, immunophenotype, 
cytogenetics, classification, treatment, hematopoietic stem cell transplantation
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons ttribution License (http://creativecommons.org/lice ses/by/3.0), which permits unrestricted use,
distribution, a d reproduction in any edium, provided the original work is properly cited.
1. Introduction
1.1. Epidemiology
Acute leukemia is the most common childhood malignancy, accounting for almost 35% of all 
childhood cancers. It can be further divided into two main subtypes such as acute lympho-
blastic leukemia (ALL), composing 80% of acute leukemia and acute myeloid leukemia (AML) 
which makes up 15–20% of acute leukemia in pediatric patients [1]. The incidence of AML is 
greatest in infants at 1.5 per 100,000 individuals per year and decreases to 0.4 per 100,000 indi-
viduals aged 5–9 years. After this, the incidence of AML begins to gradually increase reaching 
its highest point in individuals greater than 65 years of age at 16.2 per 100,000 individuals [1, 2]. 
A report using data from the surveillance, epidemiology, and end results (SEER) program 
identified Asian and Pacific Islanders to have the highest rate of childhood AML (0.84 per 
100,000) followed by Hispanics (0.81 per 100,000), Caucasians (0.75 per 100,000), and African-
Americans (0.66 per 100,000) [3, 4].
1.2. Etiology and pathophysiology
The majority of AML cases appear as a de novo malignancy in previously healthy individuals, 
but there have been cases reported in which AML presents as a secondary malignancy. This 
has been witnessed in individuals with underlying hematological and genetic disorders such 
as Fanconi Anemia, Bloom Syndrome, Ataxia Telangiectasia, Shwachman-Diamond syndrome, 
Noonan syndrome, and Dyskeratosis Congenita. The most common genetic factor for the devel-
opment of AML is trisomy 21 [3]. Children with Down syndrome have a 500-fold increased risk 
of developing a unique megakaryoblastic subtype of AML. This classically follows a transient 
myeloproliferative disorder in the neonatal period, which is characterized by somatic muta-
tions in the GATA1 gene [3, 5]. Recently, a familial predisposition to AML has been suggested, 
as a number of germ-line mutations, such as GATA2, CEBPA, TP53, and RUNX1 have been 
found in families with an unexplained high risk of AML [3, 6–10]. In addition, exposure to prior 
therapy involving topoisomerases II, alkylating agents and radiation therapy have also been 
associated with an increased risk of developing AML as a secondary malignancy [1, 3].
The pathogenesis of AML involves the abnormal proliferation and differentiation of a clonal 
population of myeloid stem cells [11]. It is thought to arise from at least two classes of cooper-
ating genetic events, known as a two-hit model of leukemogenesis [12–14]. Type I mutations 
result in increased and uncontrolled activation of pro-proliferative pathways of the leukemic 
cell and often involve activating genes that are part of signal transduction pathways, such as 
FLT3 (28% of cases), K/NRAS, TP53, and c-KIT (12, 8, and 4%, respectively) [15]. Type II muta-
tions occur as a result of genetic aberrations in hematopoietic transcription factors leading to 
the impairment of normal hematopoietic differentiation. The most common type II cytogenic 
abnormalities in children, accounting for almost half of all pediatric AML cases are, t(8;21)
(q22;q22) in the core-binding factor AML (CBF-AML) and t(15;17)(q;22;q21) in acute promy-
elocytic leukemia (APL) [16–19]. Other translocations are specific only to children and rarely 
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found in adults and these include t(1;22)(p13;q13), t(7;12)(q36;p13), and t(11;12)(p15;p13) 
[20–23]. The NPM1 and CEBPA, type II mutations, are found in approximately 27 and 6% of 
cases, respectively, and indicate a better prognosis [15]. Moreover, enhanced tyrosine phos-
phorylation of signal transducer and activator of transcription 3 (STAT3), involved in the 
stimulation of cellular proliferation and survival, is seen in almost 50% of AML cases and 
signifies a worse prognosis [24–26]. As stated by the two hit model of leukemogenesis, the 
pathogenesis of AML is dependent on two classes of cooperating genetic events. A study 
done by Patel et al. found that the c-KIT mutation has been associated with t(8,21) or inv.
(16). Furthermore, they found that NMP1, which is a type II mutation, frequently occurs 
with FLT3-ITD (a type I mutation) or with mutations in epigenetic genes such as DNMT3A 
and IDH-1 or IDH-2 [27]. Despite these advancements in the pathogenesis of AML, there still 
remains much to be discovered on the exact implications that these individual mutations 
have on the development of AML, particularly in pediatric patients.
2. Therapeutic considerations
2.1. Classification
The first classification system used to distinguish between the different subtypes of AML 
was the French-American-British (FAB) classification system established in 1976. It identifies 
eight subtypes of AML (M0-M7) based on the morphological and cytochemical characteris-
tics of the leukemic cells. The FAB classification was replaced by WHO in 2001 which was 
then revised in 2008 [28]. The WHO classification of AML was once again revised in 2016, 
this time integrating genetic information such as, karyotypes and molecular aberrations, with 
morphology, immunophenotype, and clinical presentation. It defines six major disease enti-
ties: AML with recurrent genetic abnormalities; AML with myelodysplasia-related features; 
therapy-related AML; AML not otherwise specified; myeloid sarcoma; and myeloid prolifera-
tion related to Down syndrome (Table 1) [29].
In Table 1, the subtypes of AML with recurrent genetic abnormalities are listed in accordance 
to their distinct chromosomal translocation. The newly incorporated provisional category of 
AML with mutated RUNX1 appears to represent a biologically distinct group with a worse 
prognosis in comparison to other AML subtypes. The category of AML with myelodyspla-
sia-related changes remains to include a history of MDS as an inclusion criteria, however 
has been re-structured to better include subtypes with features suggesting a poor prognosis. 
Lastly, the myeloid proliferations of Down syndrome include transient abnormal myelopoi-
esis and myeloid leukemia associated with Down syndrome. As mentioned previously, both 
subtypes involve megakaryoblastic proliferations and are characterized by GATA1 mutations 
and mutations of the JAK-STAT pathway. Transient abnormal myelopoiesis typically occurs 
at birth or within the first few days of birth and resolves within 1–2 months. Myeloid leuke-
mia associated with Down syndrome occurs later, but within the first 3 years of life, with or 
without prior transient abnormal myelopoiesis [29].
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In pediatric patients, specifically under the age of 2, it is important to search for translocations 
that are specific for pediatric AML, as WHO classification does not represent them as new 
disease categories due to their rarity. These translocations, mentioned above, include t(7;12)
(q36;p13) and t(11;12)(p15;p13) [1, 29].
2.2. Diagnostic approach
AML is a highly heterogeneous disease in regards to its morphology, immunophenotyping, 
and its clinical manifestations [1]. The clinical presentation of AML commonly manifests with 
leukocytosis, anemia, and thrombocytopenia. Fatigue, anorexia, and weight loss are less com-
monly seen and symptoms such as lymphadenopathy and organomegaly are not usually 
present. If a patient is left untreated, death will most likely occur secondary to an infection or 
bleeding [11]. In order to establish a diagnosis of acute leukemia, 20% or more blasts must be 
Types Genetic abnormalities
AML with recurrent genetic 
abnormalities
AML with t(8:21)(q22;q22); RUNX1-RUNX1T1
AML with inv.(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 APL with 
PML-RARA
AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A
ML with t(6;9)(p23;q34.1); DEK-NUP214
AML with inv.(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM AML 
(megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1 AML with BCR-ABL1 
(provisional entity)
AML with mutated NPM1
AML with biallelic mutations of CEBPA
AML with mutated RUNX1 (provisional entity)
AML with myelodysplasia-
related changes
Therapy-related myeloid 
neoplasms
AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic/monocytic leukemia acute erythroid leukemia
Pure erythroid leukemia
Acute megakaryoblastic leukemia acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to 
Down syndrome
Transient abnormal myelopoiesis
ML associated with Down Syndrome
Abbreviations: WHO, World Health Organization; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; 
ML, myeloid leukemia.
Table 1. WHO classification of AML and related neoplasms [29].
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found in the bone marrow or peripheral blood [30]. To further diagnose AML, a combination 
of analyses is required, including, morphology, immunophenotyping, cytochemistry, and 
leukemic blasts derived from peripheral blood or bone marrow demonstrating cytogenic and 
molecular characteristics [31]. Although there is some overlap between the diagnostic recom-
mendations for AML in children and adults, there are important differences between these 
two age groups that need to be focused on.
Morphological examination is conducted from blood and bone marrow smears using a May-
Grunwald-Giemsa or a Wright-Giemsa stain [30]. The FAB classification is used to define the 
morphological characteristics of AML, which are based on the lineage of associated pheno-
types: undifferentiated, myeloid, monoblastic, erythroblastic, or megakaryoblastic [32]. By 
looking at the morphology of AML, it is possible to determine the percentage of undiffer-
entiated, atypical, or granulated blasts, intracellular structures such as Auer Rods and the 
presence of myelodysplasia [31]. Auer Rods are comprised of needle-shaped, azurophilic, 
cytoplasmic inclusion bodies and are commonly seen in APL, acute myelomonocytic leuke-
mia and in majority of cases of AML with t(8;21) [28]. Once the lineage has been established 
through morphology, cytochemistry is then used to confirm the affiliation as well as differ-
entiate between myeloid (myeloperoxidase [MPO]-positive) and monoblastic (nonspecific 
esterase-positive) classification. In certain cases in which the morphology and cytochemis-
try provide an ambiguous picture, immunophenotyping is required to further support the 
appropriate diagnosis [31].
Immunophenotyping is necessary to distinguish between AML and ALL. It is also required 
to classify minimally differentiated AML (FAB M0) and acute megakaryoblastic leukemia 
(AMKL, FAB M7). In minimally differentiated AML, morphological and cytochemical evalua-
tion do not reveal myeloid differentiation. Although cytochemistry is negative for MPO activ-
ity, immunophenotyping is positive for myeloid markers, such as MPO (proenzyme) and/or 
CD13, CD33, and CD117 [31, 32]. AMKL is a type of leukemia with 20% or more blasts but of 
this, 50% or more are of megakaryocytic lineage. Immunophenotyping in AMKL is positive 
for platelet markers, such as CD41 and/or CD61 [30, 31]. The current WHO 2016 classifica-
tion has not changed significantly from the 2008 classification. Markers required to assign 
lineages and define otherwise not specified mixed phenotype acute leukemia (MPAL) include 
MPO, lysozyme, CD11c, CD14, CD64, nonspecific esterase cytochemistry, i(intracellular)
CD3, CD19, iCD22, CD79, and CD10 [29]. Table 2 presents the suggested antigen panel for 
immunophenotypic analysis required for the diagnosis of AML in pediatric patients. It was 
modified specifically for pediatric patients by Creutzig et al. from the recommended panel for 
AML in adults [30, 31].
The use of conventional cytogenetic analysis for the diagnosis of AML is a necessary com-
ponent of the diagnostic evaluation. It allows for the detection of chromosomal abnormali-
ties in 70–80% of pediatric patients with AML [31]. In the case of which cytogenetic analysis 
fails, fluorescence in situ hybridization (FISH) is an option to detect gene rearrangement. 
FISH allows for the detection of fusion genes, such as RUNX1-RUNX1T1, CBFB-MYH11, 
MLL, and EVI1 as well as the loss of chromosome 5q and 7q material [33, 34]. As previously 
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 mentioned, the two most common cytogenetic abnormalities in children are t(8;21)(q22;q22) 
in CBF-AML and t(15;17)(q;22;q21) in APL, together making up approximately 50% of pedi-
atric AML [16–19].
Molecular genetics can be performed on bone marrow and/or blood specimens. Both DNA 
and RNA should be extracted, however if there is a small amount of specimen with a limited 
number of cells, RNA extraction is preferred. This is because RNA is more suitable for molec-
ular screening for fusion genes and mutations specific to leukemia [30]. The frequency and 
nonrandom associations of type I and type II mutations (stated previously in Section 1.2) dif-
fer between pediatric and adult patients with AML [35]. Mutations in the RAS-RAF-ERK sig-
nal transduction pathway (PTPN11, NF-1, N-RAS, K-RAS) occur in 5–21% of pediatric AML 
cases and even more frequently in cases with CBF-AML and MLL-rearranged AML in young 
children. C-KIT mutations occur in 4% of all leukemia types, except CBF-AML, in which the 
incidence raises to approximately 25% in children [15, 30]. Despite the differences between 
children and adults in the expression of type I and type II mutations routine evaluation as 
suggested by Creutzig et al. should include FLT2-ITD, WTI, C-KIT, CEBPA, and NPM1 [31].
Gene expression profiling has the ability to contribute to the accurate diagnosis and risk-
stratification of pediatric AML patients. However, its use remains limited as large cohorts 
are required for validation of the true prognostic significance of these genes [36]. Biobanking 
is strongly recommended for all patients, allowing for confirmation of initial diagnosis, or 
adding new data in the case of a relapse. Stored material should include AML blasts, DNA, 
and RNA. Buccal swabs are also recommended to be stored as they allow for discrimination 
between germ line and somatic genetic aberrations. This material can be used to identify new 
prognostic markers, monitoring for minimal residual disease (MRD) and contribute to research 
studies about the biological mechanism, subgroups and leukemogenesis of AML [30, 31].
2.3. Prognostic factors
The most relevant prognostic factors for the survival of pediatric AML are genetic and molec-
ular abnormalities and the initial response to treatment. Both of these prognostic factors are 
Diagnosis of AML Mandatory Markers to fulfill WHO & EGIL 
Criteria
Other Markers
Precursor stage CD34, CD117 CD133, HLA-DR
Myelomonocytic markers CD11b, CD11c, CD13, CD14, CD15, CD33,  
CD64, CD65, iMPO, i-lysozyme
CD4, CD36, CD184 (CXCR4)
Megakaryocytic markers CD41, CD61 CD42
Erythroid marker CD235a
Leukemia specific antigen NG2 homolog
Lineage aberrant antigens CD2, CD7, CD19, CD56
Pan-leukocyte markers CD11a, CD45
Table 2. Immunophenotypic markers in Pediatric Patients for the diagnosis of AML.
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independent and are both usually essential elements of the risk group classification [31, 37]. 
Presence of a very high blast count at the time of diagnosis is associated with a higher risk of 
early death and nonresponse [38]. Other favorable prognostic factors include, t(8;21)(q22;q22)/
RUNX1-RUNX1T1, t(15;17)(q22;q21)/PML-RARA, NPM1-mutated AML and CEBPA double 
mutation - amongst a few [31]. A favorable prognostic group is CBF-AML [19, 39, 40]. MLL-
translocations have variable outcomes and depend on the associated translocation. In MLL 
t(1;11)(q21;q23) has a very favorable outcome in pediatric AML. In comparison, those with 
t(6;11)(q27;q23) and t(10;11)(p12;q23) translocations have been reported to have poor survival 
rates [31, 41, 42]. Certain prognostic makers vary between children and adults. For exam-
ple, deletion of 7q in adults is suggestive of an intermediate prognosis; however in pediatric 
patients it is associated with a poorer outcome. In these pediatric patients, the outcome has 
been found to be dependent on other cytogenetic abnormalities in the leukemia cell [19, 43]. 
Other poor prognostic abnormalities that have been described in adult AML, such as abnor-
malities of chromosomes 3q and 5q and the monsoonal karyotypes are very rare in children 
[44–47].
The type I mutations of WT1 and FLT3-itd are indicative of a poor prognosis. FLT3-itd out-
come depends on the allele ratio, whereas both of these mutations are described as events in 
clonal emulation towards relapse [48].
2.4. Pediatric AML treatment
The current survival rate of children with AML has increased to approximately 70%. This 
increase has been achieved by better risk stratification and intensification of  chemotherapeutic 
regimens. The treatment of childhood AML should be risk adapted according to various bio-
logical factors in order to avoid over treatment in patients with a favorable prognosis and pro-
vide adequate chemotherapy to improve outcome in those with a less favorable prognosis [31]. 
This allows for the destruction of leukemia cells with the hope of avoiding side effects or as 
little late side effects as possible. With regards to infant AML, the most powerful prognostic 
factor for the outcome has been found to be favorable cytogenetics and a blast count of less 
than 5% after induction therapy [49].
The standard chemotherapeutic regimen consists of a combination of 4–5 cycles of cytarabine 
and anthracycline-based regimens with allogenic stem cell transplantation in appropriate 
patients [1]. Induction therapy typically includes 1 or 2 cycles of chemotherapy in both children 
and adults. Standard induction therapy involves 3 days of an anthracycline and 7–10 days 
of cytarabine (“3 + 7” or “3 + 10”). This induction regimen achieves complete remission in 
greater than 85% of children and adolescence. A third drug, such as etoposide or 6-thiogua-
nine, can be included in induction, but their benefits have not yet been proven [50]. There are 
a number of various anthracyclines that have been evaluated through randomized controlled 
pediatric trials. Daunorubicin and mitoxantrone resulted in similar overall survival; however 
treatments with a mitoxantrone base resulted in lower relapse rates [51]. In comparison, iad-
rubicin and liposomal daunorubicin had similar survival rates, but liposomal daunorubicin 
was more effective in cases with a RUNX1/RUNX1T1 translocation and caused less treatment-
related mortality [52]. Studies have shown that higher doses of anthracyclines improve the 
outcome in children and adults [53, 54]. However, at higher doses there is an increased risk 
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for toxicity, especially acute and late cardiotoxicity. A cumulative dose of >300 mg/m2 has 
been associated with significant later cardiac toxicity and should take into consideration fac-
tors such as the patients age and sex [55, 56]. To avoid reaching peak serum concentrations, 
suggestions of splitting the dose, or using prolonged drug infusions have been proposed, 
however there have been conflicting benefits of dose scheduling and no conclusion on the best 
regimen has yet been reached [57, 58]. Dexrazozane is another option to reduce cardiotoxicity 
during anthracycline exposure and has been proven to be beneficial [59]. Failure of induction 
therapy is seen in 10–15% of pediatric patients. The subsequent outcomes for a patient with 
induction failure are similar to the patient with AML who relapsed early (<12 months after 
remission) [60, 61]. These patients, similar to patients that have relapsed, have been shown 
to have the highest end free survival after stem cell transplantation in comparison to after 
chemotherapy (31.2 vs. 5%, p < 0.0001) [62].
A considerable challenge in the treatment of children with AML is to prolong the initial remis-
sion. This is done with additional chemotherapy, similar to that in induction, but with the 
addition of non-cross-resistant drugs and high dose (HD) cytarabine [63, 64]. The ideal num-
ber of post remission cycles of therapy remains unclear, but appears to require at least two 
courses of intensive therapy, with the addition of the induction course. A study done by the 
United Kingdom Medical Research Council randomly assigned adult and pediatric patients 
to four or five courses of intensive therapy. There was no advantage seen in relapse free and 
overall survival in patients treated with five courses [51, 65].
The benefits of the intensification of cytarabine have been studied by a number of trials. In 
most studies, intensification of cytarabine from 12 to 36 g/m2 did not improve survival in adult 
AML patients [66]. However, a study by the Cancer and Leukemia Group B (CALGB) in 
adults showed that four courses of HD cytarabine (3 g/m2 per every 12 h on days 1, 3, and 5) 
were superior to four courses of lower dose cytarabine (100 mg/m2 continuous intravenously 
on days 1–5) but only in patients with CBF-AML and CN-AML [63, 67]. Several pediatric 
trials (NOPHO AML 93, AML-BFM 2004, AML 10, and AML99 of the JPLSG) showed that 
the use of intensive chemotherapy courses that include HD cytarabine reduced relapse 
rates [67–72].
Hematopoietic stem cell transplantation (HSCT) is used as post remission consolidation 
therapy. Allogenic HSCT (allo-HSCT) has been found to have a greater benefit than autol-
ogous HSCT (auto-HSCT). Several trials have found no benefit of auto-HSCT compared 
with nonmyeloablative chemotherapy during the first complete remission [69, 73–76]. In 
addition, the degree of toxicity associated with the conditioning regimen greatly out ways 
the benefits/use of auto-HSCT [77]. In comparison, prospective trials of transplantation 
in children with AML suggest that 60–70% of children with HLA-matched donors will 
experience long-term remissions when treat with an allo-HSCT during their first remis-
sion [69, 74]. Although there is a significantly lower relapse risk associated with allo-HSCT 
as compared with post-remission chemotherapy, the improvement in overall survival is 
controversial [78–80]. The current utilization of allo-HSCT involves incorporation of risk 
classification to determine whether transplantation should occur during the first remis-
sion. There is consensus that favorable-risk patients should not be transplanted in first 
complete remission but only after the first relapse and achievement of a second complete 
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remission [73, 78, 79, 81]. Some benefit has been shown in allo-HSCT during first complete 
remission in intermediate- and high-risk patients. A meta-analysis combining the results 
of the POG-8821, CCG-2891, COG-2961, and MRC-Leuk-AML-10 showed benefit for allo-
HSCT in intermediate-risk patients only [78]. Weakness in this analysis was due to a large 
percentage of patients not assigned to a risk group resulting in potential selection bias. 
If transplantation is chosen in pediatric AML, myeloablative chemotherapy is preferred 
over total body irradiation as the latter is associated with an increased risk of secondary 
malignancies and more late effects [82–84]. A large prospective CIBMTR cohort study of 
children and adults with AML, MDS, and CML, showed superior survival of patients in the 
early stages of the disease and less toxicity with busulfan-based regimens as compared to 
total body irradiation [85]. Despite these results, the optimal preparative regimen remains 
undetermined [86–88]. In summary, the role of HSCT in pediatric patients with AML in the 
first complete remission should continue to be assessed, particularly within specific risk 
groups. However, there is a consensus that HSCT should be offered to all children with 
relapsed AML once second remission has been achieved and that favorable-risk patients 
should not be offered HSCT [79].
The presence of CNS involvement at diagnosis and at relapse is seen in 5–10% of childhood 
AML cases. An increased risk of CNS involvement is seen in patients with hyperleukocyto-
sis, monocytic leukemia (FAB M4 and M5, especially those with inv(16) or 11q23 chromo-
somal abnormalities), MLL gene rearrangement, and younger age [89]. All pediatric patients 
receive CNS treatment, even if no CNS involvement is detected. This is done with the pre-
sumption that systemic chemotherapy has little efficacy in penetrating the blood–brain-bar-
rier to eradicate any potential AML blasts in the CNS. The most common regimen used for 
CNS treatment involves intrathecal chemotherapy-single agent cytarabine or methotrexate, 
or triple  cytarabine, methotrexate and hydrocortisone. Other treatments such as cranial irra-
diation have also proven to be effective in the treatment of CNS involvement in pediatric 
AML. According to European protocols, prophylactic cranial radiotherapy is used in pediat-
ric patients with AML. This is based on German pediatric AML studies, BFM-78 and BFM-83 
where the use of cranial irradiation suggested to prevent both CNS and systemic relapse 
[89, 90]. However, due to its high side effect profile (including late toxicities and secondary 
malignancies), prophylactic cranial irradiation still remains controversial and is used less fre-
quently in other countries [90].
As a result of AML being a highly heterogeneous disease and its ability to present in dif-
ferent ways, management may vary based on age group or the type of AML. One special 
group is children with DS, as they have a 14–20-fold risk of developing leukemia. In addi-
tion to the increased risk of AML during the first 3 years of life, about 10% of neonates with 
DS also develop a TMD, which usually disappears spontaneously [91]. Despite TMD self-
resolving within 4–10 weeks, it can cause severe and life threatening complications such as 
hydrops fetalis, pleural effusions, liver cirrhosis with hyperbilirubinemia, organomegaly, or 
hyperleukocytosis [92]. Approximately, 10–20% of these patients will develop myeloid leu-
kemia with megakaryoblastic features (ML-DS) within the first 3 years. Treatment of ML-DS 
involves intensity reduced chemotherapy and no HSCT in the first complete remission. As 
children with DS are susceptible to chemotherapy, the event free survival and survival rates 
are >85% [92–95].
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APL is a distinct subtype of AML and is characterized by t(15;17). This translocation 
involves a breakpoint that includes the retinoic acid receptor and leads to production of 
the promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARA) fusion protein [96]. 
Treatment is usually begun immediately with all-trans retinoid acid (ATRA) as APL is 
associated with an increased risk of a life threatening hemorrhage. In children, a dose of 
25 mg/m2 per day of ATRA should be started and has shown to produce equivalent out-
comes to the higher dose of 45 mg/m2 per day that is commonly used in adults [97–99]. 
Arsenic trioxide has proven to be an effective agent in combination with ATRA in the 
treatment of newly diagnosed, refractory, or relapsed APL [77]. In patients with hyper-
leukocytosis treated with ATRA or arsenic trioxide, approximately 10% of children can 
develop APL differentiation syndrome. This syndrome is characterized by fever, weight 
gain, respiratory distress, pleural, and pericardial effusions. The incidence of APL differen-
tiation syndrome can be reduced by combining ATRA with chemotherapy. Pseudotumor 
cerebri occurs in 11% of children during initial ATRA administration and can be treated 
with steroids [97, 100].
Although there have been major improvements in treatment outcomes, AML remains a 
life-threatening malignancy. Approximately, 30% of pediatric patients relapse, with only 
30–40% of these relapsed patients surviving, indicating a poor outcome [101, 102]. AML is a 
highly heterogeneous disease and through gaining knowledge on its molecular and genetic 
background it will allow new targeted and patient-specific therapies to become available to 
children.
2.5. Supportive treatment
The estimated incidence in children with high-risk AML of severe bacterial infections is 
50–60% and the estimated incidence of invasive fungal infections is 7.0–12.5% [103–105]. The 
improved outcome in children with AML over the last 10 years may be associated to better 
supportive care strategies.
Hyperleukocytosis (WBC greater than 100,000/μL) at initial diagnosis is associated with an 
increased risk of CNS hemorrhage and leukostasis. Patients with monocytic or myelomono-
cytic (FAB M4 and M5) as well as APL and hyperleukocytosis are at an increased risk of early 
death [106, 107]. Treatment involves emergency care with intensive monitoring and careful 
hydration with the addition of rasburicase [108]. In more severe cases involving symptomatic 
coagulopathy, exchange transfusion or leukapheresis may be required. Controlled and effec-
tive reduction in cells with enforced diuresis or hemodialysis, may prevent the occurrence of 
tumor lysis syndrome [106–108].
Hematopoietic growth factors such as granulocyte-macrophage colony-stimulating factor 
(GM-CSF) or granulocyte colony-stimulating factor (G-CSF) during AML induction ther-
apy are not recommended in the pediatric population. Although a randomized study in 
children with AML evaluated G-CSF administered after induction chemotherapy showed 
a reduction in duration of neutropenia there was no difference in infectious complica-
tions or mortality [109]. In addition, a higher relapse rate has been recently demonstrated 
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for children who over express the differentiation defective G-CSF receptor isoform IV 
[110]. Therefore, the routine prophylactic use of G-CSF or GM-CSF is not recommended 
for children with AML but remains an option in shortening neutropenia in critically ill 
patients.
Bacterial infections occur in up to 70% of children during AML therapy [111]. A ret-
rospective study from St. Jude Children’s Research Hospital (SJCRH) in patients with 
AML found that the use of intravenous cefepime or vancomycin in conjunction with oral 
ciprofloxacin or a cephalosporin significantly reduced the incidence of bacterial infection 
and sepsis compared with patients receiving only oral or no antibiotic prophylaxis [112]. 
Another retrospective study reported a significant reduction in Gram positive, sterile-
site infections with antibiotic prophylaxis [113]. While it is suggested that antibiotic pro-
phylaxis is beneficial, prospective randomized trials are required in pediatric patients 
with AML.
The incidence of invasive fungal infections is up to 15% in children with AML, which 
is similar to that in adults. They are most commonly caused by Candida and Aspergillus 
species [114]. Prophylaxis should be administered to all children with agents such as vori-
conazole, itraconazole, micafungin, or caspofungin. Due to drug interactions (e.g., itra-
conazole and voriconazole) and variable pharmacokinetics, voriconazole should be held 
during courses of chemotherapy and levels should be monitored periodically. Prophylaxis 
for Pneumocystis jirovecii with trimethoprim-sulfamethoxazole should also be adminis-
tered [114, 115].
3. Conclusion
The diagnosis and treatment of AML has significantly improved over the past decades. Risk 
stratification has allowed for more targeted and specific therapy while avoiding, over treat-
ment in low-risk patients and allowing for more intensive therapy in others. AML is a highly 
heterogeneous disease and through gaining knowledge on its molecular and genetic back-
ground as well as international collaboration, it will allow new targeted and patient-specific 
therapies to become available, particularly in pediatric patients.
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